121 completed, 26 terminated, 11 active not recruiting, 11 recruiting. 183 Phase 3, 33 Phase 2.
Follow Dyskinesias: new trials by email Literature Review of Dyskinesias trials Research Report on Dyskinesias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pivotal Study of N-acetyl-L-leucine for CACNA1A N-Acetyl-L-Leucine, Placebo - CACNA1A, Spinocerebellar Ataxia Type 6 | Phase 3 | Active not recruiting | IntraBio Inc | 60 | 2026-08-17 | 2026-11-03 |
| Pridopidine Phase 3 Study in Huntington's Disease Pridopidine, Placebo - Huntington Disease | Phase 3 | Recruiting | Prilenia | 400 | 2026-07-01 | 2026-11-04 |
| An Extension of SKY-0515 in Participants With Huntington's Disease SKY-0515 - Huntington's Disease (HD) | Phase 2 / Phase 3 | Enrolling by invitation | Skyhawk Therapeutics, Inc. | 500 | 2026-04-10 | 2026-07-24 |
| A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease Votoplam (blinded), Placebo - Huntington Disease | Phase 3 | Recruiting | Novartis Pharmaceuticals | 770 | 2026-03-24 | 2026-09-22 |
| Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease SKY-0515, SKY-0515 Placebo - Huntington Disease | Phase 2 / Phase 3 | Recruiting | Skyhawk Therapeutics, Inc. | 400 | 2026-01-06 | 2026-11-06 |
| A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) KarXT, KarX-EC - Alzheimer Disease, Agitation | Phase 3 | Recruiting | Bristol-Myers Squibb | 650 | 2025-12-02 | 2026-10-16 |
| A Randomized, Parallel-arm, Double Blind, Placebo-controlled Study to Assess the Efficacy of Fampridine for Patients With Spinocerebellar Ataxia SCA27B Caused by a GAA Expansion in the FGF14 Gene Fampridine 10 mg prolonged-release tablet (per os), Placebo (tablets per os) - Spinocerebellar Ataxia 27B (SCA27B) | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 70 | 2025-10-21 | 2025-12-10 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo - Alzheimer's Disease | Phase 3 | Recruiting | Bristol-Myers Squibb | 426 | 2025-07-16 | 2026-11-03 |
| A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG GLM101 (Part A, Double-blind), Placebo (Part A, Double-blind), GLM101 (Part B, Open-label) - Phosphomannomutase 2 Deficiency, PMM2-CDG | Phase 2 / Phase 3 | Active not recruiting | Glycomine, Inc. | 50 | 2025-07-09 | 2026-08-14 |
| Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease SKY-0515, SKY-0515 Placebo - Huntington Disease, Huntingtons Disease | Phase 2 / Phase 3 | Active not recruiting | Skyhawk Therapeutics, Inc. | 120 | 2025-05-27 | 2026-05-01 |
| A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T) N-Acetyl-L-Leucine, Placebo - Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T) | Phase 3 | Active not recruiting | IntraBio Inc | 60 | 2025-03-18 | 2026-11-04 |
| Acute Agitation in Emergency Psychiatry Sublingual Dexmedetomidine, Buccal midazolam, Oral lorazepam - Agitation | Phase 2 / Phase 3 | Recruiting | Lone Baandrup | 132 | 2024-12-30 | 2025-01-01 |
| Open-Label Extension of EryDex Study IEDAT-04-2022 Dexamethasone sodium phosphate - Ataxia Telangiectasia | Phase 3 | Terminated | Quince Therapeutics S.p.A. | 101 | 2024-12-11 | 2026-05-05 |
| An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study AXS-05 (dextromethorphan-bupropion) - Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | Phase 3 | Terminated | Axsome Therapeutics, Inc. | 139 | 2024-11-21 | 2026-06-25 |
| Effects of Dexmedetomidine on Agitation in Critically Ill TBI Patients Dexmedetomidine, Placebo - Traumatic Brain Injury, Agitation,Psychomotor | Phase 2 / Phase 3 | Not yet recruiting | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | 72 | 2024-10-01 | 2024-10-01 |
| Evaluate the Neurological Effects of EryDex on Subjects With A-T Dexamethasone sodium phosphate, Placebo - Ataxia Telangiectasia | Phase 3 | Completed | Quince Therapeutics S.p.A. | 105 | 2024-06-24 | 2026-04-30 |
| TREAT-SC: Early, Short Course Oral Dexamethasone for the Treatment of Sydenham Chorea in Children Dexamethasone Oral, Placebo - Rheumatic Fever, Sydenham Chorea | Phase 3 | Recruiting | Starship Child Health, Te Toka Tumai Auckland | 80 | 2024-06-17 | 2025-06-24 |
| Efficacy and Safety of NestaCell® in Huntington's Disease NestaCell® - Huntington Disease | Phase 3 | Unknown | Azidus Brasil | 120 | 2024-06-08 | 2023-10-24 |
| Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada Valbenazine - Chorea, Huntington | Phase 3 | Enrolling by invitation | Neurocrine Biosciences | 7 | 2024-04-24 | 2026-06-18 |
| Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis Oxymetazoline 0.1% (Pf) Oph Soln Ud, Preservative free lubricating drops - Blepharoptosis, Synkinesis | Phase 3 | Completed | Milton S. Hershey Medical Center | 36 | 2024-01-11 | 2026-03-09 |
Showing 20 of 183. Sign in to see all of them.
Psychomotor Agitation (54) · Huntington Disease (29) · Parkinson Disease (29) · Alzheimer Disease (26) · Dementia (13) · Tardive Dyskinesia (13) · Torticollis (13) · Spinocerebellar Ataxias (11) · Tremor (11) · Schizophrenia (9) · Movement Disorders (8) · Chorea (7) · Dystonia (7) · Parkinsonian Disorders (7)
Nervous System Diseases (164) · Neurologic Manifestations (153) · Pathological Conditions, Signs and Symptoms (142) · Signs and Symptoms (139) · Central Nervous System Diseases (131) · Brain Diseases (112) · Neurodegenerative Diseases (103) · Movement Disorders (77) · Mental Disorders (75) · Neurocognitive Disorders (62) · Basal Ganglia Diseases (60) · Aberrant Motor Behavior in Dementia (54) · Behavior (54) · Neurobehavioral Manifestations (54)
Botulinum Toxins, Type A (12) · Dexmedetomidine (12) · abobotulinumtoxinA (7) · valbenazine (7) · deutetrabenazine (6) · Haloperidol (4) · Jejunostomy (4) · Loxapine (4) · brexpiprazole (4) · carbidopa, levodopa drug combination (4) · Levodopa (3) · Riluzole (3) · Saline Solution (3) · Sodium Chloride (3) · Tablets (3)
Otsuka Pharmaceutical Development & Commercialization, Inc. (10) · Neurocrine Biosciences (7) · Adamas Pharmaceuticals, Inc. (6) · Ipsen (6) · Axsome Therapeutics, Inc. (5) · BioXcel Therapeutics Inc (5) · AbbVie (prior sponsor, Abbott) (4) · Auspex Pharmaceuticals, Inc. (4) · Kissei Pharmaceutical Co., Ltd. (4) · Assistance Publique - Hôpitaux de Paris (3) · Quince Therapeutics S.p.A. (3) · Skyhawk Therapeutics, Inc. (3) · Addex Pharma S.A. (2) · Alexza Pharmaceuticals, Inc. (2) · Azidus Brasil (2)
United States (115) · Canada (45) · Germany (40) · France (34) · Spain (31) · United Kingdom (31) · Italy (25) · Poland (25) · Australia (19) · Czechia (18) · Austria (15) · Portugal (14) · Hungary (11) · Israel (11) · Belgium (10)
Janet Benesh (4) · Eva Kohegyi, MD (3) · Angela Dentiste, MBA (2) · BioXcel MM (2) · BioXcel MM, MD (2) · Christopher Kenney, MD (2) · Constantine Lyketsos, MD, MHS (2) · Dirk Thye, MD (2)
PMID 38557959, PMID 40681915, PMID 41533472, PMID 41961243, PMID 25962554, PMID 39108660, PMID 41591746, PMID 19126811, PMID 20359934, PMID 20519680, PMID 23667214, PMID 24361112, PMID 25185211, PMID 25324317, PMID 26666500, PMID 28265459, PMID 29163985, PMID 29532440, PMID 31617235, PMID 31708380, PMID 31779508, PMID 33461041, PMID 33864229, PMID 34024025, PMID 34115419, PMID 35747889, PMID 36002761, PMID 39825184, PMID 40265997, PMID 40847656, PMID 41439450, PMID 41626017, PMID 41689409, PMID 42052145, PMID 42502037, PMID 11087767, PMID 11133600, PMID 11473855, PMID 15689584, PMID 16216957, PMID 16381181, PMID 16677266, PMID 17052655, PMID 17416907, PMID 17685739, PMID 18175337, PMID 18312060, PMID 19058133, PMID 19064745, PMID 19454631
2014 (3), 2017 (3), 2023 (3), 2005 (2), 2008 (2), 2018 (2), 2025 (2), 1RC2AG036535 (1), 2004 (1), R01AG031348 (1), R01AG052510 (1), R01MH059666 (1), R01MH070802 (1), R01NR015226 (1), R01NS052619 (1)